Merck Sues Novartis Unit Over Cancidas ANDA

Law360, New York (April 6, 2010, 1:45 PM EDT) -- Merck & Co. Inc. has accused Novartis AG subsidiary Sandoz Inc. of patent infringement through its efforts to introduce a generic version of anti-fungal drug Cancidas.

The complaint, lodged March 30 in the U.S. District Court for the District of New Jersey, alleges Sandoz has infringed the formulation patent for Cancidas by filing an abbreviated new drug application with the U.S. Food and Drug Administration.

Sandoz claims in the ANDA that its proposed caspofungin acetate drug does not violate Merck's formulation patent for Cancidas, according to...
To view the full article, register now.